← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Bicycle Therapeutics plc (BCYC) 10-Year Financial Performance & Capital Metrics

BCYC •
HealthcareBiotechnologyDrug Discovery and Antibody Platforms
AboutBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Show more
  • Revenue $35M +30.8%
  • EBITDA -$203M -10.5%
  • Net Income -$169M +6.4%
  • EPS (Diluted) -2.90 +42.9%
  • Gross Margin -390.34% +18.7%
  • EBITDA Margin -574.61% +15.5%
  • Operating Margin -594.96% +15.5%
  • Net Margin -479.18% +28.5%
  • ROE -29.04% +48.4%
  • ROIC -
  • Debt/Equity 0.01 -90.1%
  • Interest Coverage -121.31 -108.4%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong 5Y sales CAGR of 20.6%
  • ✓Trading at only 0.4x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Shares diluted 63.5% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y20.65%
3Y44.48%
TTM-23.2%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-50.75%

EPS CAGR

10Y-
5Y-
3Y-
TTM-9.73%

ROCE

10Y Avg-49.17%
5Y Avg-33.56%
3Y Avg-33.94%
Latest-29.65%

Peer Comparison

Drug Discovery and Antibody Platforms
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
REGNRegeneron Pharmaceuticals, Inc.107.56B781.6718.840.99%31.41%14.41%3.79%0.09
CTMXCytomX Therapeutics, Inc.430.14M5.3714.1336.45%24.66%26.09%
PRTCPureTech Health plc405.3M16.778.3944.98%-495.91%-8.53%0.05
DNAGinkgo Bioworks Holdings, Inc.327.53M6.75-1.20-25.06%-183.81%-61.5%0.82
BCYCBicycle Therapeutics plc111.38M5.73-1.9830.76%-8.85%-40.53%0.01
CCCCC4 Therapeutics, Inc.261.67M2.70-2.13-100%-40.92%0.23
MOLNMolecular Partners AG187.84M5.02-2.43-29.38%-10.87%-63.06%0.02
RXRXRecursion Pharmaceuticals, Inc.1.94B3.67-2.5526.92%-8.65%-57.01%0.07

Compare BCYC vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs REGN

Compare head-to-head with Regeneron Pharmaceuticals, Inc.

vs CNTA

Compare head-to-head with Centessa Pharmaceuticals plc

Compare Top 5

vs REGN, CNTA, IMNM, CLDX

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+02.06M7.14M13.8M10.39M11.7M14.46M26.98M35.27M
Revenue Growth %--246.41%93.4%-24.72%12.58%23.65%86.52%30.76%
Cost of Goods Sold+269.29K11.87M20.76M25.54M33.15M00156.5M172.97M
COGS % of Revenue-576.02%290.93%185.06%319.05%--580.13%490.34%
Gross Profit+-269.29K-9.81M-13.63M-11.74M-22.76M11.7M14.46M-129.52M-137.69M
Gross Margin %--476.02%-190.93%-85.06%-219.05%100%100%-480.13%-390.34%
Gross Profit Growth %--3541.44%-38.95%13.84%-93.88%151.4%23.65%-995.53%-6.31%
Operating Expenses+13.22M18.27M28.88M14.56M29.2M77.31M131.12M60.43M72.18M
OpEx % of Revenue-887.04%404.74%105.5%281.05%660.98%906.56%224%204.62%
Selling, General & Admin3.45M6.41M8.12M14.56M29.2M32.44M49.51M59.83M71.46M
SG&A % of Revenue-311.02%113.8%105.5%281.05%277.29%342.3%221.8%202.59%
Research & Development9.77M11.87M20.76M31.64M33.15M44.88M81.61M156.5M172.97M
R&D % of Revenue-576.02%290.93%229.26%319.05%383.69%564.26%580.13%490.34%
Other Operating Expenses0-119K-665K-31.64M-33.15M00-155.9M-172.25M
Operating Income+-13.49M-16.21M-21.75M-26.3M-51.96M-65.62M-116.65M-189.95M-209.87M
Operating Margin %--787.04%-304.74%-190.56%-500.1%-560.98%-806.56%-704.13%-594.96%
Operating Income Growth %--20.15%-34.13%-20.94%-97.57%-26.29%-77.78%-62.83%-10.49%
EBITDA+-13.22M-15.88M-21.04M-25.34M-50.68M-64.21M-112.96M-183.4M-202.69M
EBITDA Margin %--770.75%-294.78%-183.6%-487.81%-548.94%-781.06%-679.86%-574.61%
EBITDA Growth %--20.06%-32.48%-20.46%-100.02%-26.69%-75.93%-62.35%-10.52%
D&A (Non-Cash Add-back)269.29K335.56K710.8K960K1.28M1.41M3.69M6.55M7.18M
EBIT-13.53M-16.21M-22.24M-26.3M-51.96M-65.5M-110.9M-189.95M-172.07M
Net Interest Income+050K169K814K226K-2.86M2.41M10.74M32.55M
Interest Income8K50K169K814K683K120K5.76M14M34.28M
Interest Expense0000457K2.98M3.34M3.26M1.73M
Other Income/Expense-37.9K-69K-496K-4.56M226K-2.86M2.41M10.74M36.08M
Pretax Income+-13.53M-16.28M-22.24M-30.86M-51.73M-68.48M-114.24M-179.21M-173.8M
Pretax Margin %--790.39%-311.69%-223.62%-497.92%-585.47%-789.88%-664.32%-492.69%
Income Tax+-20.94K-23K-396K-254K-724K-1.66M-1.52M1.46M-4.76M
Effective Tax Rate %99.85%99.86%98.22%99.18%98.6%97.57%98.67%100.81%97.26%
Net Income+-13.51M-16.26M-21.85M-30.61M-51.01M-66.82M-112.72M-180.66M-169.03M
Net Margin %--789.27%-306.14%-221.78%-490.95%-571.25%-779.35%-669.72%-479.18%
Net Income Growth %--20.34%-34.36%-40.11%-66.66%-30.99%-68.69%-60.28%6.44%
Net Income (Continuing)-13.51M-16.26M-21.85M-30.61M-51.01M-66.82M-112.72M-180.66M-169.03M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+-0.76-1.22-1.64-2.77-2.66-2.67-3.80-5.08-2.90
EPS Growth %--60.53%-34.43%-68.9%3.97%-0.38%-42.32%-33.68%42.91%
EPS (Basic)-0.76-1.22-1.64-2.77-2.66-2.67-3.80-5.08-2.91
Diluted Shares Outstanding17.7M13.29M13.29M11.05M19.15M25.06M29.66M35.59M58.21M
Basic Shares Outstanding17.7M13.29M13.29M11.05M19.15M25.06M29.66M35.59M58.21M
Dividend Payout Ratio---------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+11.29M71.51M76.77M104.15M155.72M458.56M369.38M561.87M928.61M
Cash & Short-Term Investments9.4M67.66M63.38M92.12M135.99M438.68M339.15M526.42M879.52M
Cash Only9.4M67.66M63.38M92.12M135.99M438.68M339.15M526.42M879.52M
Short-Term Investments000000000
Accounts Receivable1.37M3M11.31M7.14M14.63M11.91M21.21M24.04M35.65M
Days Sales Outstanding-531.73578.65188.97514.06371.65535.2325.26368.91
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets1.37M000009.02M11.41M13.43M
Total Non-Current Assets+549K2.49M4.86M6.05M5.43M21.24M41.23M33.48M28.26M
Property, Plant & Equipment519K1.36M1.82M4.35M3.61M17.79M32.77M27.68M17.19M
Fixed Asset Turnover-1.51x3.93x3.17x2.88x0.66x0.44x0.97x2.05x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments0000000547K547K
Other Non-Current Assets30K1.13M3.04M1.7M1.82M3.45M8.46M5.24M10.53M
Total Assets+11.84M74M81.63M110.19M161.15M479.79M410.61M595.34M956.87M
Asset Turnover-0.03x0.09x0.13x0.06x0.02x0.04x0.05x0.04x
Asset Growth %-525.27%10.3%35%46.24%197.73%-14.42%44.99%60.73%
Total Current Liabilities+3.81M9.45M8.93M8.82M23.13M36.24M53.34M69.54M67.23M
Accounts Payable1.88M2.06M1.89M1.95M1.36M2.72M6.47M13.05M15.79M
Days Payables Outstanding2.55K63.5233.1827.8515.03--30.4433.33
Short-Term Debt00000004.88M0
Deferred Revenue (Current)03.98M10K728K10.13M19.27M20.42M24.98M10.19M
Other Current Liabilities1.54M148K5.42M2.58M6.39M7M13.4M13.24M35.74M
Current Ratio2.96x7.57x8.60x11.81x6.73x12.65x6.92x8.08x13.81x
Quick Ratio2.96x7.57x8.60x11.81x6.73x12.65x6.92x8.08x13.81x
Cash Conversion Cycle---------
Total Non-Current Liabilities+0111.73M142.52M8.18M42.56M97.3M86.48M154.88M96.58M
Long-Term Debt000014.51M29.87M30.32M30.7M0
Capital Lease Obligations0001.25M426K12.08M10.88M9.38M3.99M
Deferred Tax Liabilities000000000
Other Non-Current Liabilities0101.25M127.9M2M2.61M3.28M3.83M4.58M1.12M
Total Liabilities3.81M121.19M151.45M17M65.69M133.54M139.83M224.41M163.81M
Total Debt+0001.89M15.78M44.34M44.33M44.96M9.49M
Net Debt-9.4M-67.66M-63.38M-90.23M-120.22M-394.34M-294.83M-481.47M-870.03M
Debt / Equity---0.02x0.17x0.13x0.16x0.12x0.01x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage-----113.70x-21.99x-34.88x-58.21x-121.31x
Total Equity+8.02M-47.18M-69.83M93.2M95.46M346.25M270.78M370.93M793.06M
Equity Growth %--688.04%-47.99%233.47%2.43%262.72%-21.8%36.98%113.8%
Book Value per Share0.45-3.55-5.258.444.9913.829.1310.4213.62
Total Shareholders' Equity8.02M-47.18M-69.83M93.2M95.46M346.25M270.78M370.93M793.06M
Common Stock3K5K10K227K266K384K387K550K890K
Retained Earnings-31.84M-48.1M-69.94M-100.55M-151.56M-218.38M-331.1M-511.76M-680.79M
Treasury Stock0-837K0000000
Accumulated OCI-2.29M69K-1.75M-1.53M-3.19M-3.39M387K-1.3M119K
Minority Interest000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-11.27M-1.42M-26.08M-28.61M-17.79M-14.79M-86.11M-60.63M-164.72M
Operating CF Margin %--68.69%-365.44%-207.33%-171.21%-126.48%-595.39%-224.75%-466.97%
Operating CF Growth %-87.44%-1742.97%-9.72%37.83%16.84%-482.07%29.59%-171.7%
Net Income-13.51M-16.26M-21.85M-30.61M-51.01M-66.82M-112.72M-180.66M-169.03M
Depreciation & Amortization269.29K332K712K960K1.28M1.41M3.69M6.55M7.17M
Stock-Based Compensation123K515K1.02M3.08M6.51M12.08M26.78M32.48M38.08M
Deferred Taxes0119K00-673K-1.67M-4.98M3.31M-5.23M
Other Non-Cash Items182.52K856K665K5.38M751K2.14M442K1.04M-2.26M
Working Capital Changes1.85M13.02M-6.63M-7.43M25.35M38.06M672K76.66M-33.46M
Change in Receivables-1.16M-1.42M-400K4.91M-2.15M4.54M-11.35M-1.2M-11.95M
Change in Inventory00-2.12M-2.55M4.16M-4.79M000
Change in Payables1.64M67K-169K220K-663K1.2M2.56M8M3.1M
Cash from Investing+-243.36K-1.11M-1.19M-1.55M-1.2M-2.03M-18.99M-2.93M-1.24M
Capital Expenditures-243.36K-1.11M-1.19M-1.55M-1.2M-2.03M-18.99M-2.93M-1.24M
CapEx % of Revenue-54.03%16.62%11.27%11.55%17.35%131.28%10.86%3.5%
Acquisitions000000000
Investments---------
Other Investing000000000
Cash from Financing+16.77M57.88M25.43M58.44M62.84M320.73M6.69M250.03M519.75M
Debt Issued (Net)000015M15M00-31.91M
Equity Issued (Net)01000K1000K1000K1000K1000K1000K1000K1000K
Dividends Paid000000000
Share Repurchases00-576K000000
Other Financing16.77M1K1K149K-301K7.18M989K682K7.53M
Net Change in Cash3.46M58.26M-4.28M28.74M43.87M302.69M-99.53M187.82M353.1M
Free Cash Flow+-11.51M-2.53M-27.26M-30.17M-18.99M-16.82M-105.1M-63.56M-165.96M
FCF Margin %--122.72%-382.06%-218.59%-182.76%-143.83%-726.67%-235.61%-470.47%
FCF Growth %-78.04%-978.48%-10.65%37.06%11.4%-524.69%39.53%-161.12%
FCF per Share-0.65-0.19-2.05-2.73-0.99-0.67-3.54-1.79-2.85
FCF Conversion (FCF/Net Income)0.83x0.09x1.19x0.93x0.35x0.22x0.76x0.34x0.97x
Interest Paid0000378K2.52M2.79M2.75M1.37M
Taxes Paid0073K117K124K73K2.23M562K792K

Key Ratios

Metric201620172018201920202021202220232024
Return on Equity (ROE)-168.37%---261.92%-54.08%-30.25%-36.53%-56.31%-29.04%
Return on Invested Capital (ROIC)----663.67%-----
Gross Margin--476.02%-190.93%-85.06%-219.05%100%100%-480.13%-390.34%
Net Margin--789.27%-306.14%-221.78%-490.95%-571.25%-779.35%-669.72%-479.18%
Debt / Equity---0.02x0.17x0.13x0.16x0.12x0.01x
Interest Coverage-----113.70x-21.99x-34.88x-58.21x-121.31x
FCF Conversion0.83x0.09x1.19x0.93x0.35x0.22x0.76x0.34x0.97x
Revenue Growth--246.41%93.4%-24.72%12.58%23.65%86.52%30.76%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.